-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SAR-442501 in Achondroplasia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SAR-442501 in Achondroplasia Drug Details:SAR-442501 is under development for the treatment of achondroplasia and osteochondrodysplasia. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Influenza (Quadrivalent) Vaccine in Influenzavirus B Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Influenza (Quadrivalent) Vaccine in Influenzavirus B Infections Drug Details:Vaccine is under development for the prevention of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Pancreatic CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-300 in Hepatitis B
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VTP-300 in Hepatitis BDrug Details:VTP-300 is under development for the treatment of hepatitis B. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-200 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VTP-200 in Cervical CancerDrug Details:VTP-200 is under development for the treatment of HPV associated cervical cancer...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-200 in Cervical Intraepithelial Neoplasia (CIN)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VTP-200 in Cervical Intraepithelial Neoplasia (CIN)Drug Details:VTP-200 is under development for the treatment of HPV associated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-200 in Human Papillomavirus (HPV) Associated Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VTP-200 in Human Papillomavirus (HPV) Associated CancerDrug Details:VTP-200 is under development for the treatment of HPV...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BI-1819479 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BI-1819479 in Idiopathic Pulmonary Fibrosis Drug Details:BI-1819479 is under development for the treatment of unspecified indication,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KER-047 in Iron Deficiency Anemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.KER-047 in Iron Deficiency AnemiaDrug Details:KER-047 is under development for the treatment of functional iron deficiency anemia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Racemic Ketamine in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Racemic Ketamine in Parkinson's DiseaseDrug Details:Ketamine is under development for the treatment of status epilepticus, rett...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-600 in Squamous Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VTP-600 in Squamous Non-Small Cell Lung CancerDrug Details:VTP-600 is under development for the treatment of non-squamous...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-850 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.VTP-850 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:VTP-850 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ketamine in Parkinson’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ketamine in Parkinson's Disease Drug Details: Ketamine is under development for the treatment...
-
Product Insights
Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Middle East Respiratory Syndrome (MERS) Pipeline Drugs Market Report Overview Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. The MERS pipeline drugs market research report provides comprehensive information on the MERS targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players...
-
Product Insights
Cervical Intraepithelial Neoplasia (CIN) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cervical Intraepithelial Neoplasia Pipeline Drugs Market Overview Cervical Intraepithelial Neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge, and low back pain. The CIN pipeline drugs market research report provides comprehensive information...
-
Product Insights
![]()
Net Present Value Model: VTP-200
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VTP-200 Drug Details VTP-200 is under...
-
Product Insights
![]()
Net Present Value Model: VTP-300
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VTP-300 Drug Details VTP-300 is under...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-300
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VTP-300 Drug Details VTP-300 is under development for the treatment of hepatitis B. It...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-200
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VTP-200 Drug Details VTP-200 is under development for the treatment of HPV associated cervical...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.